Jonathan Welden, MD
Endocrinology, Diabetes & Metabolism · Baton Rouge, LANPI 1194935635
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 92.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $15,075 and has fallen 96.5% since, to $531 in 2025.
Across 116 payments — averaging $209.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$22K
- Novo Nordisk$743
- BETA Bionics, Inc.$346
- Amgen$235
- Sequel Med Tech, LLC$154
- Xeris Pharmaceuticals, Inc.$139
- plus $301 from 8 others
What the payments were for
- Consulting fees$3,18013%
- Speaking & faculty fees$14,00058%
- Travel & lodging$4,63819%
- Food & beverage$2,40210%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 72 | $22,346 |
| Novo Nordisk | 11 | $743 |
| BETA Bionics, Inc. | 12 | $346 |
| Amgen | 2 | $235 |
| Sequel Med Tech, LLC | 2 | $154 |
| Xeris Pharmaceuticals, Inc. | 8 | $139 |
| Ascendis Pharma Endocrinology Inc | 1 | $119 |
| Ascensia Diabetes Care US Inc. | 1 | $44 |
| AbbVie | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Dexcom, Inc. | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,264 in reported general payments places this provider in the 80th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 451 | $634,026 |
| JardianceEmpagliflozin | 417 | $344,913 |
| MounjaroTirzepatide | 221 | $261,373 |
| JanuviaSitagliptin Phosphate | 118 | $108,231 |
| TrulicityDulaglutide | 56 | $74,517 |
| SynthroidLevothyroxine Sodium | 970 | $71,872 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 61 | $65,248 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $63,206 |
| RybelsusSemaglutide | 51 | $60,596 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $58,961 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $53,524 |
| Humulin R U-500Insulin Regular, Human | 21 | $42,220 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 279 | $41,124 |
| Novolog FlexpenInsulin Aspart | 131 | $37,450 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $35,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $743 | $702,147523 claims |
| Lilly USA, LLCMounjaro, Trulicity | $22,346 | $335,890277 claims |
| AbbVieSynthroid | $40 | $71,872970 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Baton Rouge
- Timothy GilbertBaton Rouge$985K
- Frank GreenwayBaton Rouge$42K
- Ivan GamboaBaton Rouge$25K
- Brittani BreauxBaton Rouge$18K
- Lourdes RodriguezBaton Rouge$17K
- Robin KilpatrickBaton Rouge$12K
- Lauren CutroneBaton Rouge$11K
- Jolene JohnsonBaton Rouge$10K
- Shatha MuradBaton Rouge$2K
- Roopitha KavalBaton Rouge$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.